



P Dell'orto

Contact

P Dell'orto

Publications (3)

Luen S, Regan M, Colleoni M, Di Leo A, Viale G, Thürlimann B, Hackl W, Demanse D, Biasi O, Dell'orto P, Kammler R, Savas P, Lee C, Asher R, Loi S. Identifying oncogenic drivers associated with increased risk of late distant recurrence in postmenopausal, estrogen receptor-positive, HER2-negative early breast cancer: results from the BIG 1-98 study. *Ann Oncol* 2020; 31:1359-1365.

Oakman C, Harvey V, Punzalan L, Dell'orto P, Larsimont D, Steinberg I, Gelber R, Piccart-Gebhart M, Viale G, Gutiérrez J, Thürlimann B, Jakesz R, Francis P, Crown J, Quinaux E, Buyse M, De Azambuja E, Margeli Vila M, Andersson M, Nordenskjöld B, Di Leo A. Overall survival benefit for sequential doxorubicin-docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer--8-year results of the Breast International Group 02-98 phase III trial. *Ann Oncol* 2013; 24:1203-11.

Viale G, Thürlimann B, Mouridsen H, Mauriac L, Gelber R, Price K, Goldhirsch A, Gusterson B, Coates A, Láng I, Colleoni M, Regan M, Dell'orto P, Mastropasqua M, Maiorano E, Rasmussen B, Macgrogan G, Forbes J, Paridaens R, for the BIG 1-98 Collaborative and International Breast Cancer Study Groups. Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial. *Ann Oncol* 2011; 22:2201-2207.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch